Business Wire

VA-REGULA

Share
Regula Responds to Forensic Experts' Needs with Fast and Intuitive Operating Software

Regula, a global developer of forensic devices and identity verification solutions, has released a significant update to its operating software, Regula Forensic Studio. This major revamp enhances the functionality of forensic devices, improves usability, streamlines operations, and allows for more precise document examination.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702630951/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A forensic expert examines a banknote with the help of a Regula device and Regula Forensic Studio software (Photo: Regula) 

Compatible with Regula’s most recent advanced forensic devices, including the company’s flagship dual-video spectral comparator, Regula 4308, Regula Forensic Studio software facilitates manual examination of handwritten texts, banknotes, travel and identity documents, collectibles, and more. Supplied in a bundle with forensic devices and available out-of-the-box, Regula Forensic Studio can operate all Regula devices in a forensic laboratory, creating a smooth user experience and allowing for a wide range of examinations.

The new features and improvements in Regula Forensic Studio significantly elevate the user experience, as well as the convenience, speed, and accuracy of forensic examination.

Crucial examination speed and precision enhancements include:

  • A new cross-platform architecture that significantly streamlines document processing and reporting, and ensures full compatibility with all popular operating systems, such as Windows, Linux, and macOS.
  • The possibility of creating predefined scenarios (macros) for repetitive tasks, which makes it possible to automate the verification process for certain types of documents. For example, if an expert needs to verify a wad of banknotes, they can automatically record the sequence of checks (including all the lighting and filtering techniques) for one banknote, and auto-repeat it for the rest of the wad. Not only does this feature streamline the whole process, but also eliminates human-related errors.
  • Fully automated ID verification in mere seconds through seamless integration with Regula Document Reader SDK, which instantly recognizes the document type and validates all its data from MRZs, RFID chips, barcodes, and performs available security checks.
  • Enhanced integration with the Information Reference System (IRS), which makes it simple to compare an examined document to its reference image from the database. Thanks to real-time sync between RFS and the Information Reference System, the device's active light source is switched to the one used in the reference sample, and vice versa. This leads to more quick and efficient examinations.
  • Automated banknote residual area measurement, a new feature that was added as a response to customers’ needs. It uses banknote references from the Regula IRS to automatically measure the undamaged area of a banknote and determine if it can be accepted by the bank.

Key usability enhancements include:

  • A new intuitive user-friendly interface.
  • Multi-screen support to allow users to drag and drop application tabs between monitors, which is especially convenient when working with several images.
  • Colored image superimposition, a new feature that highlights different elements of two images for easier comparison.
  • Pseudocolor visualization, a feature that uses substitute bright colors to highlight areas within the same color (like some indistinguishable shades of gray) for better visualization.
  • Automatic detection of Machine Identification Code (MIC), a new feature that detects a unique yellow-dot pattern color laser printers and copiers leave on paper sheets. This helps identify the source of printed documents.

“In the crowded field of ID verification, Regula has distinguished itself by constantly improving, as well as adopting a customer-centric approach at the core of our research and development. The updated Regula Forensic Studio software has become notably faster and more efficient. It reflects feedback from external forensic experts and our customers, and incorporates features designed to address specific use cases and improve operations. This user-centric approach helps us boost the functionality of our solutions and meet the evolving needs of our customers in the most efficient way,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To see the full list of new features and capabilities and learn more about the recent update of Regula Forensic Studio, please visit Regula’s website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702630951/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye